Loading clinical trials...
Loading clinical trials...
Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.
Age
50 - 90 years
Sex
ALL
Healthy Volunteers
No
Xiaoxin Li
Beijing, Beijing Municipality, China
Start Date
January 1, 2008
Primary Completion Date
June 1, 2010
Completion Date
December 1, 2010
Last Updated
March 2, 2011
210
ACTUAL participants
Bevacizumab 1
DRUG
Bevacizumab
DRUG
Lead Sponsor
Peking University People's Hospital
NCT04200248
NCT05703867
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02355028